Sacituzumab Govitecan

• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical st… Pending
  2024-516734-35-00 Phase III 1 country WSG Westdeutsche Studiengruppe GmbH
• Bladder Preservation with Sacituzumab Govitecan + Zimberelimab for MuscleInvasive Bladder cancer in cisplatin-unfit and unwilling for cystec… Pending
  2024-516943-14-01 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
• A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacitu… Pending
  2024-517561-16-00 Phase II 1 country AIO-Studien gGmbH
• Testing two different drugs (sacituzumab-govitecan and trastuzumab-deruxtecan) combinations prescribed in an alterning pattern to patients w… Pending
  2025-521909-40-00 Phase II 1 country Unicancer
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting
  2024-515884-69-00 Phase III 11 countries Gilead Sciences Inc.
• Sacituzumab govitecan (SG) with bevacizumab for the treatment of brain metastases from non-small cell lung cancer (NSCLC) Recruiting
  2024-514066-40-00 Phase II 1 country Academisch Ziekenhuis Maastricht
• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting
  2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
• Study of treatment with sacituzumab and zimkberelimab for patients with lung cancer confined to the chest and previously operated on who wer… Recruiting
  2024-512960-75-00 Phase III 1 country Fundacion GECP
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 Phase III 6 countries Gilead Sciences Inc.
• NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br… Recruiting
  2023-508787-29-00 Phase II 1 country WSG Westdeutsche Studiengruppe GmbH
• A multicenter, open label, two cohort, single arm, phase II study to evaluate the efficacy and safety of the anti-TROP2 antibody-drug conjug… Recruiting
  2023-504898-20-00 Phase II 1 country Grupo Espanol De Tumores Neuroendocrinos
• Biomarker analysis in patients with metastatic breast cancer treated with sacituzumab govitecan. Recruiting
  2023-505385-28-00 Phase II 1 country Solti Group
• Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer – a multicenter, open-label, umbrella phase-II study … Recruiting
  2024-514022-23-00 Phase II 1 country Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
• A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting
  2023-508302-24-00 Phase II 5 countries Gilead Sciences Inc.
• An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patien… Ended
  2023-504420-26-00 Phase II 1 country Fundacion Para El Progreso De La Oncologia En Cantabria
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother… Ended
  2024-511957-23-00 Phase III 7 countries Gilead Sciences Inc.
• Safety and efficacy analysis of an antibody associated with a chemotherapy for patients with a triple negative metastatic breast cancer. Ended
  2022-502369-10-00 Phase III 2 countries Unicancer
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended
  2022-502593-17-00 Phase III 11 countries Gilead Sciences Inc.
• A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin… Ended
  2024-518486-10-00 Phase II 1 country Associacio Per A La Recerca Oncologica
• SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan, and bladder-saving approach, for… Ended
  2024-514569-20-00 Phase II 1 country Ospedale San Raffaele S.r.l.
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U… Ended
  2023-504194-21-00 Phase III 10 countries Gilead Sciences Inc.
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable… Ended
  2023-504195-14-00 Phase III 12 countries Gilead Sciences Inc.
• A Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors Ended
  2024-513611-28-00 Phase II 3 countries Gilead Sciences Inc.
• A Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non−Small-Cell Lung Ca… Ended
  2024-513225-23-00 Phase II 4 countries Gilead Sciences Inc.

Showing 1–24 of 32 trials